SGK
VRTX icon

Steigerwald Gordon & Koch’s Vertex Pharmaceuticals VRTX Stock Holding History

Steigerwald Gordon & Koch’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83K Hold
167
– – 0.01% 239
2026
Q1 		$74.6K Hold
167
– – 0.01% 250
2025
Q4 		$75.7K Hold
167
– – 0.01% 253
2025
Q3 		$65.4K Buy
+167
New +$69.8K 0.01% 264

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Steigerwald Gordon & Koch's VRTX Position: Q2 2026 in Review

Steigerwald Gordon & Koch held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 167 shares worth $83K. The position accounts for 0.01% of the portfolio, ranked #239.

Steigerwald Gordon & Koch first reported a position in VRTX in Q3 2025 and has held it in 4 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Steigerwald Gordon & Koch held 167 shares of Vertex Pharmaceuticals worth $83K as of Q2 2026.
  • Steigerwald Gordon & Koch left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up 0.01% of Steigerwald Gordon & Koch's portfolio in Q2 2026, its #239 holding.
  • Steigerwald Gordon & Koch first reported a position in Vertex Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Steigerwald Gordon & Koch's 13F filing for Q2 2026, filed 23 Jul 2026.